Wean Early With High-Flow Nasal Cannula Oxygenation Versus Noninvasive Positive Pressure Ventilation in Patients With Acute Hypoxemic Respiratory Failure: a Multicenter, Randomized, Controlled Trial (the WHEN Study)

Beijing Chao Yang Hospital1 site in 1 country270 target enrollmentJune 1, 2017

ConditionsPatients With Acute Hypoxemic Respiratory Failure

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Patients With Acute Hypoxemic Respiratory Failure
Sponsor: Beijing Chao Yang Hospital
Enrollment: 270
Locations: 1
Primary Endpoint: Duration of invasive mechanical ventilation
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The main purpose of the present study is to verify whether, as compared with conventional weaning, early weaning with high-flow nasal cannula oxygenation or noninvasive positive pressure ventilation may more effective in shortening the duration of invasive ventilation, hence reducing the rates of complications and mortality in patients with acute hypoxemic respiratory failure.

Registry

clinicaltrials.gov

Start Date

June 1, 2017

End Date

March 31, 2022

Last Updated

4 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Beijing Chao Yang Hospital

Responsible Party

Principal Investigator

Zujin Luo

Beijing Chao Yang Hospital

Eligibility Criteria

Inclusion Criteria

•Orotracheal intubation；
•PaO2 \<60mmHg（venturi mask，FiO2=0.5），and PaCO2 ≤45mmHg；
•Meeting criteria for weaning readiness；
•Spontaneous breathing trial failure.

Exclusion Criteria

•Duration of invasive ventilation \<48h；
•Tracheotomy；
•Percentage of cuff leak volume in tidal volume\<15.5%；
•Unable to spontaneously clear secretions from their airway；
•Recent oral，nasal，facial or cranial trauma or surgery；
•Recent gastric or esophageal surgery；
•Active upper gastro-intestinal bleeding；
•Severe abdominal distension；
•Lack of co-operation；
•Chronic respiratory disease such as chronic obstructive pulmonary disease, asthma, interstitial lung disease and neuromuscular disease.